Eurofins to Acquire Majority Stake in Ajal for Laboratories, to Expand its Food and Pharmaceutical Products Testing Offering in the Kingdom of Saudi Arabia
2022年6月2日 - 2:15PM
ビジネスワイヤ(英語)
Regulatory News:
Eurofins Scientific (Paris:ERF) (EUFI.PA), the global leader in
food, environment, pharmaceutical and cosmetic product testing and
in agroscience contract research services, announces it has entered
into a partnership with the shareholders of Saudi Ajal, the parent
company, to successfully complete the acquisition of a majority
stake in Ajal for Laboratories, a food, tobacco and pharmaceutical
testing laboratory based in Riyadh, Kingdom of Saudi Arabia
(“KSA”).
Ajal for Laboratories is one of the leading food and
pharmaceutical testing laboratories in the KSA and the Gulf
Cooperation Council area, generating around €15m revenue in 2021.
Located in Riyadh, the laboratory comprises a 3,000 m² footprint
and is equipped with state-of-the-art testing equipment and
technology, facilitating GC/MS and LC/MS analytical techniques
among others. In addition to having achieved ISO17025
accreditation, the laboratory is one of the few laboratories in the
KSA to be approved by the SFDA (Saudi Food and Drug Authority) and
the Ministry of the Environment, Water and Agriculture.
Ajal for Laboratories was established in 2009 and has since
grown quickly under the leadership of its Managing Director,
Mohammed Al Soghaier, and its Chairman, Mohammed Al Sultan, to
become one of the leading food and pharmaceutical laboratories in
the region. Having worked together closely in the past, Eurofins
and Ajal for Laboratories’ partnership will be further strengthened
through this transaction. This is Eurofins’ first acquisition in
the Kingdom of Saudi Arabia and represents a commitment to building
a network of local and regional laboratories to support customers
in the Middle East, and the rapidly growing food production and
biopharma sectors in the KSA.
Notes to Editors:
For more information, please visit www.eurofins.com
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. Eurofins is the global leader in
food, environment, pharmaceutical and cosmetic product testing, and
in discovery pharmacology, forensics, advanced material sciences
and agroscience Contract Research services. Eurofins is also a
market leader in certain testing and laboratory services for
genomics, and in the support of clinical studies, as well as in
BioPharma Contract Development and Manufacturing. The Group also
has a rapidly developing presence in highly specialised and
molecular clinical diagnostic testing and in-vitro diagnostic
products.
With 58,000 staff across a decentralised and entrepreneurial
network of 900 laboratories in 54 countries, Eurofins offers a
portfolio of over 200,000 analytical methods to evaluate the
safety, identity, composition, authenticity, origin, traceability
and purity of a wide range of products, as well as providing
innovative clinical diagnostic testing services and in-vitro
diagnostic products.
The Group’s objective is to provide its customers with
high-quality services, innovative solutions and accurate results on
time. Eurofins is ideally positioned to support its clients’
increasingly stringent quality and safety standards and the
increasing demands of regulatory authorities as well as the
requirements of healthcare practitioners around the world.
In 2020 and 2021, Eurofins reacted quickly to meet the global
challenge of COVID-19, by creating the capacity to help over 20
million patients monthly who may have been impacted by the pandemic
with our testing products and our services and directly supporting
healthcare professionals working on the front line to fight the
virus. The Group has established widespread PCR testing
capabilities and has carried out over 40 million tests in its own
laboratories, is supporting the development of a number of vaccines
and has established its SAFER@WORK™ testing, monitoring and
consulting programmes to help ensure safer environments, travel and
events during COVID-19.
Eurofins has grown very strongly since its inception and its
strategy is to continue expanding its technology portfolio and its
geographic reach. Through R&D and acquisitions, the Group draws
on the latest developments in the field of biotechnology and
analytical chemistry to offer its clients unique analytical
solutions.
Shares in Eurofins Scientific are listed on the Euronext Paris
Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF
FP).
Until it has been lawfully made public widely by Eurofins
through approved distribution channels, this document contains
inside information for the purpose of Regulation (EU) 596/2014 of
the European Parliament and of the Council of 16 April 2014 on
market abuse, as amended.
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgment of
Eurofins Scientific’s management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantees can be made as to their completeness
or validity.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220601005759/en/
Investor Relations Eurofins Scientific SE Phone: +32 2 766 1620
E-mail: ir@eurofins.com
Enerplus (NYSE:ERF)
過去 株価チャート
から 6 2024 まで 7 2024
Enerplus (NYSE:ERF)
過去 株価チャート
から 7 2023 まで 7 2024